Hologic’s Multiplex COVID-19/Flu Test became commercially available in North America and Europe
On Oct. 27, 2021, Hologic announced the commercial availability of its Aptima SARS-CoV-2/Flu test in North America and…
On Oct. 27, 2021, Hologic announced the commercial availability of its Aptima SARS-CoV-2/Flu test in North America and…
On Oct. 22, 2021, the U.S. Centers for Disease Control and Prevention (CDC) reported two new U.S. human…
On Oct. 14, 2021, Cepheid announced it had received the CE mark for Xpert Xpress CoV-2/Flu/RSV plus, a…
On Oct. 7, 2021, PerkinElmer announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use…
On Oct. 7, 2021, Vaxart announced that a Duke University-led study published in bioRxiv showed that Vaxart’s (investigational…
On Oct. 1, 2021, LabCorp announced that it had received Emergency Use Authorization (EUA) from the U.S. Food…
On Sept. 29, 2021, Pfizer and BioNTech positive top-line results from a Phase 3 study (B7471004) evaluating the…
On Sept. 29, 2021, Cepheid announced it had received Emergency Use Authorization from the U.S. Food & Drug…
On Sept. 27, 2021, Pfizer announced that the first participants have been dosed in a Phase 1 clinical…
On Sept. 23, 2021, Novavax announced publication of complete results from a pivotal Phase 3 clinical trial of…
On Sept. 8, 2021, Novavax announced enrollment of the first participants in a Phase 1/2 study to evaluate…
On Jun. 17, 2021, the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research granted…
On Jun. 14, 2021, Novavax announced data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax,…
On Jun. 1, 2021, the National Institutes of Health (NIH) announced the first-in-human, Phase 1 trial assessing the…
On May 10, 2021, Novavax announced data from a preclinical study of the company’s combination quadrivalent seasonal flu…
On Apr. 15, 2021, the National Institute of Allergy and Infectious Diseases (NIAID) announced it had established a…
On Apr. 8, 2021, Oxford University announced that favipiravir was to be investigated in the UK as part…
On Mar. 30, 2021, BD (Becton, Dickinson) announced the U.S. Food and Drug Administration (FDA) granted emergency use…
On Mar. 5, 2021, Abbott announced the U.S. Food and Drug Administration’s (FDA) Emergency Use Authorization (EUA) for…
On Feb. 20, 2021, Russian authorities reported the detection of influenza A(H5N8) virus infection in seven poultry workers…
On Feb. 19, 2021, Luminex announced that it had received $11.3 million in funding from the Biomedical Advanced…
On Feb. 3, 2021, an experimental single-dose, intranasal influenza vaccine, was safe and produced a durable immune response…
On Jan. 27, 2021, a U.S. Centers for Disease Control and Prevention (CDC) study found that the 2019-2020…
On Jan. 11, 2021, Roche announced that the European Commission (EC) had approved Xofluza (baloxavir marboxil) for the…
On Jan. 11, 2021, Moderna announced that it was expanding its pipeline of innovative vaccines with three new…
On Jan. 7, 2021, Twist Bioscience announced it would supply the U.S. Centers for Disease Control and Prevention…
On Dec. 21, 2020, Quidel announced that it had received Emergency Use Authorization from the U.S. Food and…
On Dec. 7, 2020, an universal influenza virus vaccine, which produces antibodies that target the part of the…
On Dec. 4, 2020, the U.S. Food and Drug Administration (FDA) authorized the first diagnostic test for at home collection…
On Dec. 4, 2020, it was reported in JAMA that high-dose influenza (commonly known as flu) vaccines are…